Lifyorli Kit
Product Images NDC 76346-550

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lifyorli (NDC 76346-550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Corcept Therapeutics Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Relacorilant (Rel04 0002 01)

Chemical structure of Relacorilant, illustrating its molecular configuration including a trifluoromethyl-substituted pyridine ring, a sulfonamide group, and multiple heterocyclic components.*

FDA Label Image

Figure 1 (Rel04 0002 02)

Kaplan-Meier survival curve comparing progression-free survival percentages over time in months between two groups: LIFYORLI plus nab-paclitaxel and nab-paclitaxel monotherapy. The chart includes a legend and a table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 2 (Rel04 0002 03)

A Kaplan-Meier survival curve comparing overall survival percentages over time in months. The graph contrasts 'LIFYORLI + nab-paclitaxel' therapy with 'Nab-paclitaxel monotherapy,' showing survival rates decreasing over approximately 33 months. The number of subjects at risk is displayed below the time axis for both treatment groups.*

FDA Label Image

Principal Display Panel (Rel04 0002 04)

Lifyorli (relacorilant) capsules 125 mg dose kit, containing one 100 mg capsule and one 25 mg capsule. The packaging indicates a 1-dose supply with a blister card of 2 capsules. The label shows it is an oral prescription drug by Corcept Therapeutics Incorporated, with NDC 76346-425-01. Instructions for dosing and storage are also visible on the label.*

FDA Label Image

Principal Display Panel (Rel04 0002 05)

Lifyorli relacorilant capsules 125 mg Dose kit packaging label showing a 3-dose supply. The kit includes three 100 mg capsules and three 25 mg capsules. The label features dosing instructions, storage conditions, and the Corcept Therapeutics Incorporated logo, indicating the product is manufactured by Corcept Therapeutics Incorporated.*

FDA Label Image

Principal Display Panel (Rel04 0002 06)

Lifyorli dose kit containing relacorilant capsules with a total 125 mg dose composed of one 100 mg capsule and one 25 mg capsule. This 9-dose supply is packaged by Corcept Therapeutics Incorporated and includes detailed dosing instructions and multiple labeled blister card sections for tracking across days before, of, and after infusion. The kit is labelled for oral use.*

FDA Label Image

Principal Display Panel (Rel04 0002 07)

Lifyorli 125 mg Dose kit packaging label showing two capsules: one 100 mg and one 25 mg. The label includes dosing instructions to take two capsules at the same time and storage information. Manufactured by Corcept Therapeutics Incorporated, the product contains relacorilant capsules for oral use.*

FDA Label Image

Principal Display Panel (Rel04 0002 08)

Lifyorli relacorilant capsules 125 mg dose kit packaging label showing a 3-dose supply with six capsules: three 100 mg and three 25 mg capsules. The label includes dosing instructions, capsule blister layout by day, storage conditions, and manufacturer Corcept Therapeutics Incorporated.*

FDA Label Image

Principal Display Panel (Rel04 0002 09)

Lifyorli (relacorilant) capsules 150 mg dose kit packaging label for oral use by Corcept Therapeutics Incorporated. The label indicates the kit contains a 1-dose supply of three capsules: one 100 mg capsule and two 25 mg capsules. Includes dosing instructions and storage information.*

FDA Label Image

Principal Display Panel (Rel04 0002 10)

Lifyorli (relacorilant) capsules 150 mg Dose kit packaging label shows a 3-dose supply with directions to take one 100 mg capsule and two 25 mg capsules orally each day with food. The label indicates the product is an oral prescription drug by Corcept Therapeutics Incorporated, includes dosing instructions, storage information, and a barcode. The kit contains one blister card of 9 capsules.*

FDA Label Image

Principal Display Panel (Rel04 0002 11)

Lifyorli (relacorilant) capsules 150 mg dose kit for oral use, labeled by Corcept Therapeutics Incorporated. The packaging indicates a 9-dose supply with instructions to take one 100 mg capsule and two 25 mg capsules with food around the day before, day of, and day after an infusion. The label includes a dosing calendar and storage instructions.*

FDA Label Image

Principal Display Panel (Rel04 0002 12)

Lifyorli (relacorilant) capsules 150 mg dose kit by Corcept Therapeutics Incorporated. The kit includes one blister card with three capsules: one 100 mg capsule and two 25 mg capsules. The packaging provides dosing instructions to take all three capsules at the same time and storage information recommending 20°C to 25°C (68°F to 77°F).*

FDA Label Image

Principal Display Panel (Rel04 0002 13)

Lifyorli (relacorilant) capsules kit with a 150 mg total dose per day, consisting of 100 mg and 25 mg capsules. The packaging label shows a 3-dose blister supply: three 100 mg capsules and six 25 mg capsules, organized into separate daily doses labeled as the day before, day of, and day after. The labeler is Corcept Therapeutics Incorporated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.